An Analysis of the PALOMA-3 Trial
Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Clinical Pearls:
- The PALOMA-3 trial is focusing on women who have progressed on their first-line hormonal therapy - There are a number of different options in this space, but fulvestrant is one of the strongest and has the best data when given under 500mg/dose
- There is no evidence of any drug interaction between palbociclib and fulvestrant
- Adding fulvestrant to palbociclib may improve the length of time that cancer can be controlled
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More
